I agree that this site is using cookies. You can find further informations here.
X
Ponce Aix, Santiago
109  results:
Search for persons X
?
1

Toxicity of immunotherapy combinations with chemotherapy ac..:

Rached, Layal ; Laparra, Ariane ; Sakkal, Madona...
Cancer Treatment Reviews.  127 (2024)  - p. 102751 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Cabozantinib plus atezolizumab in previously untreated adva..:

Li, Daneng ; Loriot, Yohann ; Burgoyne, Adam M....
eClinicalMedicine.  67 (2024)  - p. 102376 , 2024
Link: https://doi.org/10.1016/..
 
?
3

138P Faecalibacterium prausnitzii enhances tumor response t..:

Rodriguez-Festa, A. ; Serna-Blasco, R. ; Nadal, E....
ESMO Open.  9 (2024)  - p. 102725 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Blood tumor mutational burden and response to pembrolizumab..:

Bar, Jair ; Esteban, Emilio ; Rodríguez-Abreu, Delvys...
Lung Cancer.  190 (2024)  - p. 107506 , 2024
Link: https://doi.org/10.1016/..
 
?
5

6O Subcutaneous fat mass predicts progression-free survival..:

Delaye, M. ; Lawrance, L. ; Belkouchi, Y....
ESMO Open.  9 (2024)  - p. 102261 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Antibody drug conjugates in older patients: State of the ar:

Rached, Layal ; Geraud, Arthur ; Frelaut, Maxime...
Critical Reviews in Oncology/Hematology.  193 (2024)  - p. 104212 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Capmatinib Plus Nazartinib in Patients With EGFR-Mutated No..:

Felip, Enriqueta ; Metro, Giulio ; Soo, Ross A....
European Journal of Cancer.  , 2024
Link: https://doi.org/10.1016/..
 
?
8

Cabozantinib plus atezolizumab in previously untreated adva..:

Daneng Li ; Yohann Loriot ; Adam M. Burgoyne...
http://www.sciencedirect.com/science/article/pii/S2589537023005539.  , 2024
Link: https://doi.org/10.1016/..
 
?
9

High-dose alectinib for RET fusion-positive non-small cell ..:

Dziadziuszko, Rafal ; Peled, Nir ; Mok, Tony...
Współczesna Onkologia.  27 (2023)  4 - p. 217-223 , 2023
Link: https://doi.org/10.5114/..
 
?
10

10 Osimertinib versus gefitinib followed by osimertinib in ..:

Masip, J. Remon ; Besse, B. ; Aix, S. Ponce...
Journal of Thoracic Oncology.  18 (2023)  4 - p. S35 , 2023
Link: https://doi.org/10.1016/..
 
?
11

PP01.09 Genotypic Characteristics and Resistance Mutations ..:

Castro, R. López ; Molla, A. Insa ; González, E. Esteban...
Journal of Thoracic Oncology.  18 (2023)  3 - p. e13-e14 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Ramucirumab plus erlotinib versus placebo plus erlotinib in..:

Garon, E.B. ; Reck, M. ; Nishio, K....
ESMO Open.  8 (2023)  4 - p. 101580 , 2023
Link: https://doi.org/10.1016/..
 
?
13

187P Tissue B-cell receptor repertoire as biomarker of comp..:

Sierra-Rodero, B. ; Martínez-Toledo, C. ; Molina-Alejandre, M....
Journal of Thoracic Oncology.  18 (2023)  4 - p. S141-S142 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Profile and outcome of cancer patients enrolled in contempo..:

Alouani, Emily ; Gazzah, Anas ; Mercier, Sandrine...
European Journal of Cancer.  188 (2023)  - p. 1-7 , 2023
Link: https://doi.org/10.1016/..
 
?
15

P2.14-04 Treatment Beyond Progression with Atezolizumab in ..:

García-Campelo, R. ; Dómine Gómez, M. ; de Castro, J....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S372 , 2023
Link: https://doi.org/10.1016/..
 
1-15